Inventor
Artur Mitterer
Inventor
Orth/Donau, AT
Overview
Patents· 50 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides26%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C12NMicroorganisms or enzymes19%
A61KPreparations for medical, dental or toiletry purposes15%
C12YEnzymes7%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture3%
Y02ATechnologies for adaptation to climate change3%
Y10TTechnical subjects covered by former us classification3%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests2%
C12MApparatus for enzymology or microbiology1%
PatentTitleYear
10,723,761Protein purification by anion exchange chromatography202010,696,731Oligopeptide-free cell culture media202010,378,004Protein purification by anion exchange chromatography201910,202,416Purification method for divalent cation binding proteins on anion exchange resin201910,202,417Purification method for vitamin K dependent proteins by anion exchange chromatography20199,982,286Medium for the protein-free and serum-free cultivation of cells20189,758,568'Oligopeptide-free cell culture media'20179,732,327'Formulation of sugar solutions for continuous ultracentrifugation for virus purification'20179,701,710'Protein purification by anion exchange chromatography'20179,670,456'Virus filtration of cell culture media'20179,441,203'Medium for the protein-free and serum-free cultivation of cells'20169,315,560'Purification of VWF for increased removal of non-lipid enveloped viruses'20169,127,264'Substantially animal protein-free recombinant furin and methods for producing the same'20158,969,533'Formulation of sugar solutions for continuous ultracentrifugation for virus purification'20158,945,895'Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof'20158,722,406'Medium for the protein-free and serum-free cultivation of cells'20148,399,632'Method for the purification of recombinant blood coagulation factor IX enriched in sulfated and/or phosphorylated molecules'20138,389,261'Method of isolation and purification of trypsin from pronase protease and use thereof'20138,388,847'Methods of concentrating shear-sensitive biopolymers'20138,148,502'R-ALPHA1 antitrypsin anion exchange chromatography'20128,143,347'Pegylation of recombinant blood coagulation factors in the presence of bound antibodies'20128,058,411'Method for producing mature VWF from VWF pro-peptide'20118,021,881'Medium for the protein-free and serum-free cultivation of cells'20117,659,380'Method of isolation and purification of trypsin from pronase protease and use thereof'20107,648,958'Factor VIII/vWF-complex and methods of purifying same'20107,498,146'Stable factor VIII/von willebrand factor complex'20097,223,595'Use of purified Streptomyces griseus trypsin for production of a biomass of cells and viral propagation'20076,953,837'Factor VIII/vWF complexes and compositions'20056,924,151'Stable factor VIII/vWF-complex'20056,831,159'Method for purifying factor VIII/vWF company by cation-exchange chromatography'20046,830,917'Method of isolation and purification of trypsin from pronase protease and use thereof'20046,825,027'Method of production of purified hepatitis a virus particles and vaccine preparation'20046,579,723'Method of recovering highly purified vWF or factor VIII/vWF-complex'20036,465,624'Purification of von-Willebrand factor by cation exchanger chromatography'20026,414,125'Method of chromatographically purifying or fractionating, respectively, von Willebrand factor from a VWF-containing starting material'20026,228,613'Stable factor VIII/von Willebrand factor complex'20016,103,693'Method for isolation of highly pure von willebrand factor'20006,086,871'Prothrombin derivatives'20006,034,222'Method for the separation of recombinant pro-factor IX from recombinant factor IX'20006,010,844'Methods of preparing and recovering proteins'20005,892,005'High molecular and low molecular fractions of von willebrand factor'19995,880,265'Method for isolation of highly pure von willebrand factor'19995,877,152'Method for isolation of highly pure von Willebrand Factor'19995,869,617'High and low molecular weight fractions of von Willebrand Factor and preparations of same'19995,854,403'Method for isolation of highly pure von Willebrand Factor'19985,633,350'Method for the isolation and purification of vitamin K-dependent proteins'19975,576,175'Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen'19965,340,575'Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen'19945,274,081'Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen'19934,831,121'Polydisperse native pseudomonas flagellar (H) antigens (FAg) and methods of producing them'1989Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1989–2020Based in Orth/Donau, AT· patent location history
2000–2005Patents assigned to BAXTER AG (10)· patent assignee history
2001–2010Based in Mannsdorf, AT· patent location history
2004–2015Patents assigned to BAXTER HEALTHCARE SA (12)· patent assignee history
2011–2019Patents assigned to MITTERER ARTUR (12)· patent assignee history
2012Based in Krems, AT· patent location history
2015–2020Patents assigned to BAXALTA INC (12)· patent assignee history
2015–2020Patents assigned to Baxalta GmbH (12)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BAXALTA INC | 12 | 2015–2020 |
| BAXTER HEALTHCARE SA | 12 | 2004–2015 |
| Baxalta GmbH | 12 | 2015–2020 |
| MITTERER ARTURself | 12 | 2011–2019 |
| BAXTER AG | 10 | 2000–2005 |
Locations
| Location | Patents | Span |
|---|---|---|
| Orth/Donau, AT | 40 | 1989–2020 |
| Mannsdorf, AT | 9 | 2001–2010 |
| Krems, AT | 1 | 2012 |